Carisma Therapeutics reports Q3 EPS (53c), consensus (57c)

Reports Q3 revenue $3.83M, consensus $1.2M. “During the third quarter, Carisma made several key advancements across our clinical and pre-clinical programs and reported data from both our Phase 1 clinical study of CT-0508 and our pre-clinical work with Moderna developing in vivo CAR-M,” said Steven Kelly, President and CEO of Carisma. “We continue to progress CT-0508 and CT-0525, our assets targeting HER2 overexpressing tumors, as we work to validate our first-in-class engineered macrophage platform. We believe that we have value-driving, next-generation cell therapies in our pipeline that have the potential to improve the treatments available for patients with cancer and other serious disorders.” Carisma believes that its cash, cash equivalents and marketable securities of $94.1M as of September 30, 2023, are sufficient to sustain Carisma’s planned operations into the first quarter of 2025.